Tower Research Capital (TRC)’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
Tower Research Capital (TRC)'s ARKG Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its ARK Genomic Revolution ETF (ARKG) stake by 116% in Q1 2026, buying an estimated $1.93M and bringing the position to 122,863 shares worth $3.25M. The position accounts for 0.08% of the portfolio, ranked #241.
Tower Research Capital (TRC) first reported a position in ARKG in Q2 2019 and has held it in 26 quarters since. The position peaked at $10.4M in Q1 2022. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.
- Tower Research Capital (TRC) held 122,863 shares of ARK Genomic Revolution ETF worth $3.25M as of Q1 2026.
- Tower Research Capital (TRC) bought 65,881 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $1.93M.
- ARK Genomic Revolution ETF made up 0.08% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #241 holding.
- Tower Research Capital (TRC) first reported a position in ARK Genomic Revolution ETF in Q2 2019 and has held it in 26 quarters since.
- Tower Research Capital (TRC)'s ARK Genomic Revolution ETF position peaked at $10.4M in Q1 2022.
- 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.